×
Home Companies Industry Politics Money Opinion LoungeMultimedia Science Education Sports TechnologyConsumerSpecialsMint on Sunday
×

Event Update: Ranbaxy Laboratories

Event Update: Ranbaxy Laboratories
Comment E-mail Print Share
First Published: Thu, Sep 18 2008. 10 28 AM IST
Updated: Thu, Sep 18 2008. 10 28 AM IST
In a disappointing move the USFDA has blocked 30 drugs generic drugs being manufactured out of Ranbaxy’s Dewas and Ponta Sahib facilities in India.
It has been inspecting the Ponta Sahib facility for almost two years. According to USFDA, Ranbaxy has violated the procedural issues of manufacturing.
Management is looking at addressing the concerns raised by USFDA. While it’s difficult to ascertain the loss of sales of these products according to a rough estimate the removal of these products from the US would entail a loss of sales of around 6%-10% of the overall sales of the US markets. It would not impact any of the FTF ( First-To-File) launches of the company.
Accordingly we have DOWNGRADED our US sales and target price on the stock to Rs500.
Comment E-mail Print Share
First Published: Thu, Sep 18 2008. 10 28 AM IST
More Topics: Stock Ideas | Money Matters | Equities |